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SUMMARY
The seroprevalence and geographic distribution of HTLV-1/2 among blood donors are extremely important to transfusion services. 
We evaluated the seroprevalence of HTLV-1/2 infection among first-time blood donor candidates in Ribeirão Preto city and region. From 
January 2000 to December 2010, 1,038,489 blood donations were obtained and 301,470 were first-time blood donations. All samples 
were screened with serological tests for HTLV-1/2 using enzyme immunoassay (EIA). In addition, the frequency of coinfection with 
hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV), Chagas disease (CD) and syphilis was also 
determined. In-house PCR was used as confirmatory test for HTLV-1/2. A total of 296 (0.1%) first-time donors were serologically 
reactive for HTLV-1/2. Confirmatory PCR of 63 samples showed that 28 were HTLV-1 positive, 13 HTLV-2 positive, 19 negative and 
three indeterminate. Regarding HTLV coinfection rates, the most prevalent was with HBV (51.3%) and HCV (35.9%), but coinfection 
with HIV, CD and syphilis was also detected. The real number of HTLV-infected individual and coinfection rate in the population is 
underestimated and epidemiological studies like ours are very informative.
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INTRODUCTION
Human T cell lymphotropic virus (HTLV) was discovered in 1980, 
and was the first retrovirus isolated from humans associated with a disease, 
later denominated HTLV-135. In 1982, a new member of this family was 
discovered, classified as HTLV-221 and recently two new types, HTLV-3 
and HTLV-4 were identified26,27,42. Among these, HTLV-1 is the most 
widespread and is estimated to infect 15 to 20 million people worldwide13.
Currently, HTLV-1 is etiologically associated with adult T cell 
leukemia/lymphoma43, myelopathy associated with HTLV-1 or 
tropical spastic paraparesis (HAM/TSP)33 and with other inflammatory 
manifestations including polymyositis, HTLV-1 associated arthropathy, 
infective dermatitis, uveitis, and Sjögren’s syndrome, among 
others23,28-30,32. There are different routes of HTLV transmission, i.e., 
sexual contact, transfusion of blood components, intravenous injection, 
and vertical transmission.
The seroprevalence rates differ according to geographic area, 
socio-demographic composition and individual risk behaviors. HTLV is 
endemic in Southwest Japan, in the Caribbean basin, in the southeastern 
United States, Central and South America, and in areas of Central and 
West Africa34. 
Several studies have reported that indicators of an individual’s 
low social and economical position, such as few years of education, 
are associated with HTLV-1/2 infection in endemic and non-endemic 
areas11,15,31,39. Finally, risk factors such as advanced age, female gender, 
high proviral load, sexual transmission and low immune response 
efficiency are also associated with the development of HAM/TSP2,25,37. 
The serologic test for HTLV-1/2 became mandatory in Brazilian blood 
banks in 1993 (Brazilian Ministry of Health Law nº 1376), following the 
guidelines previously established in Japan (1986) and the US (1988)5. 
Since then, several studies have been conducted with data obtained from 
the screening of HTLV-1/2 in blood banks to estimate the seroprevalence 
of the virus in various states of Brazil. Due to the large area and population 
size, it is estimated that Brazil, among all endemic countries, may host 
the largest absolute number of individuals seropositive for HTLV-1/2, 
about 2.5 million. This is based on data from blood donations and on 
only one population-based study in the State of Bahia (Northeast region)9. 
The prevalence of HTLV-1/2 among blood donors is 0.33% in 
Rio de Janeiro, 0.08% in Manaus (Amazonas State), 0.33% in Recife 
(Pernambuco State), 0.08% in Florianópolis (Santa Catarina State)19, and 
0.2% in São Paulo city17. The highest prevalence (1.35%) is observed 
among blood donors from Salvador city19. Moreover, in the same city the 
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prevalence is estimated 0.8% among pregnant women4 and 25.5% among 
intravenous drug users14. Although the prevalence of this retrovirus is 
known in several Brazilian cities, it has not yet been determined among 
candidates for blood donation in Ribeirão Preto and region, located in 
the Northwest part of São Paulo State. 
Besides HTLV-1/2, other infectious agents are also tested in Brazilian 
blood banks, including: hepatitis C virus (HCV), hepatitis B virus 
(HBV), human immunodeficiency virus type 1/2 (HIV-1/2), syphilis, and 
Chagas disease (CD). However, there are few reports on the prevalence 
of coinfection with these agents in HTLV-1/2-seropositive individuals 
in Brazilian blood banks. 
Thus, the objective of the present study was to determine the 
seroprevalence of HTLV-1/2 among blood donors from the region of 
Ribeirão Preto over an 11-year period of follow-up, as well as to analyze 
the rate of coinfection with other infectious diseases (HCV, HBV, HIV-
1/2, syphilis and CD) among donors with reactive serology for the 
anti-HTLV-1/2 marker. 
MATERIALS AND METHODS
Study Design: The study was conducted between January 2000 and 
December 2010 at the Regional Blood Center of Ribeirão Preto, São 
Paulo State, Brazil. The Regional Blood Center of Ribeirão Preto is one 
of the most important units of the network of Blood Services in São Paulo 
State and is responsible for the collection, processing and distribution 
of blood components in 213 municipalities, which correspond to a total 
of 4.3 million inhabitants. 
The procedures for blood donor selection (clinical exam and 
interview, blood collection, laboratory testing) are relatively uniform 
throughout the network, following official written guidelines issued by the 
Brazilian Ministry of Health. Blood donor candidates are submitted to a 
routine pre-donation questionnaire and clinical examination. Individuals 
considered eligible for blood donation are 18 to 60 years of age, in good 
health, and report no risk behavior for retrovirus infection (use of illegal 
injecting drugs, unsafe sexual practices, etc.) and no history of blood/
blood product transfusion in the previous ten years. 
The HTLV-1/2-positive individuals were notified about their positive 
status and referred for clinical follow up to the Neurology Department 
of the Clinical Hospital of the Faculty of Medicine in Ribeirão Preto, 
University of São Paulo. 
Laboratory serology tests: HTLV-1/2 diagnosis was established by 
screening HTLV-1/2 antibodies by enzyme immunoassay (EIA) using 
serum/plasma samples from all blood donors. During the study period, 
three different kits were used. The EIA test was selected according to 
convenience and to the supply available each year: 2000 and 2001 - 
Vironostika® HTLV-I/II (Organon Teknika Corporation, Durham, NC, 
USA); 2000 to 2009 - Ortho® HTLV-I/HTLV-II Ab-capture ELISA test 
system (Ortho Clinical Diagnostics Inc, Raritan, New Jersey). In 2006, 
2007, 2009 and 2010 Murex HTLV I+II (Murex Biotech Limited, UK) 
were also used.
Serum samples were also investigated for antibodies against hepatitis 
B virus (HBV), hepatitis C virus (HCV), human immunodeficiency 
virus (HIV), Chagas disease, and syphilis. Different commercial kits 
were used during the study period and samples were considered to be 
reactive according to the cutoff value of the manufacturer’s instructions. 
All HTLV-1/2 EIA samples that were reactive in the primary test were 
retested.
Database survey of blood donations: The results of serology 
screening and personal characteristics of blood donors were included in 
the database of the Regional Blood Center of Ribeirão Preto. The database 
information allows us to classify each blood donor as first-time, lapsed 
or regular and to identify gender and age. We defined regular donors as 
those who donated blood two or more times a year.
To obtain a genuine result the seroprevalence frequency of HTLV-
1/2 infection was determined by dividing the number of HTLV-1/2-
seropositve first-time donors by the total number of first-time donations 
tested each year. All HTLV-1/2-positive blood samples are considered to 
be inappropriate and the blood donor is referred to specialized medical 
care. The prevalence of coinfection was evaluated in first-time donors 
which were reagent to anti-HTLV-1/2 EIA. 
Coinfection status was considered when the same sample reacted to 
anti-HTLV-1/2 and to another serological marker in the screening tests 
for first-time blood donors. 
Confirmatory tests: Some HTLV-1/2 EIA reactive samples were 
confirmed by in-house polymerase chain reaction (PCR) using 5 mL of 
the intravenous blood sample collected from each blood donor in tubes 
containing EDTA as anticoagulant. Blood cells were separated from 
plasma under aseptic conditions by centrifugation at 900 x g for 10 
minutes at 4 ºC. The white cell layer was aspirated together with the red 
blood cells and placed in sterile 15 mL polypropylene tubes at -20 ºC. 
The total DNA of these samples was extracted using the Super Quick 
Gene DNA Isolation extraction kit (Analytical Genetic Testing Center 
- AGTC, Denver, Colorado, USA). The DNA obtained was quantified 
and diluted to a final concentration of 0.1 mg/mL DNA.
We then amplified the tax and LTR regions for HTLV-1 and the 
pxA, pxB, and LTR regions for HTLV-2. Reactions were performed in 
a total volume of 50 mL containing 100-200 ng of DNA, 0.25 pmol of 
each primer, 0.2 mM of dNTP, 1X PCR buffer-MgCl2 and 1.5 U Taq 
DNA polymerase. Thermocycling was performed in a GeneAmp PCR 
system 9700 (Applied Biosystems) under the following conditions: an 
initial cycle at 96 ºC for five minutes, followed by 35 cycles at 95 ºC for 
one min, 52-61 ºC for one min and 15 sec, and 72 ºC for one min and 
50 sec with a final extension step of 72 ºC for 10 min. Three mL of the 
amplified products were used in the nested PCR using a set of internal 
primers, maintaining the conditions used in the first reaction. 
The primer sequences (5’- 3’) for HTLV-1 were: Tax region - the 
external primer sequences were PX01- TCGAAACAGCCCTGCAGATA 
and PX02- TGAGCTTATGATTTGTCTTCA. The internal primer 
sequences were PXI1- ATACAAAGTTAACCATGCTT and PXI3- 
AGACGTCAGAGCCTTAGTCT18. 
LTR region - the external primer sequences were LTR1- 
CATTTCTACTCTCACACG GCCTCATACAGTACTCTT and LTR2- 
CGCAGTTCAGGAGGCACCAC. The internal primer sequences 
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were LTRN1- TTGAAGAATACACCAACATCCC and LTRN2- 
GAACGCGACTCAACCGGCGTGGAT1 
The primer sequences (5’- 3’) for HTLV-2 were: LTR region - the external 
primer sequences were BSQF6- CAGGGCGAGTCATCGACCCAAAAG 
and BSDR3- GAAGACAATGCTCCTAGGGCGGGC. The internal 
primer sequences were BSQF2- ACCGTCTCACACAAACAATCCC 
and BSDR4- GCGGGCCTGCCTATAGCGATG40.
pxA region - the external primer sequences were px101- 
GGCAATCTCCTAAAATAGTCT and px102- TGTGTGTAGGA 
ACATTTTGTA. The internal primer sequences were px103- 
TTACAATCCTGTCTCCTCTCA and px104- AAGTTCTTCTAATCG 
TTTTAG. pxB region - the external primer sequences were px105- 
GCTTTCCCCACCCATGACATG and px106- GGGCCGTGG 
TTTCAGTTCCTA. The internal primer sequences were px107- ACCCCA 
TGTCATATTCTGCCA and px108- AGCCTTTACTTGGGATTGTTT16. 
The amplified products were analyzed by 1% agarose gel electrophoresis 
followed by ethidium bromide staining. 
Statistical Analysis: Data regarding donor gender, age and different 
blood donor’s types were analyzed by the Chi-square test. The statistical 
analyses were performed using Prism 5 software (GraphPad Software, 
Inc., San Diego, CA, USA). Values of p lower than 0.05 were considered 
to be statistically significant. 
RESULTS
Seroprevalence: Between January 2000 and December 2010, 
1,038,489 voluntary blood donations were obtained from the Regional 
Blood Center of Ribeirão Preto and 301,470 were first-time blood 
donations. All samples were screened with serological tests for anti-
HTLV-1/2 (Table 1). During this period, we identified 387 (0.04%) 
samples that were reactive for anti-HTLV-1/2, including 296 (76.5%) 
samples from first-time, 49 (12.7%) from regular and 42 (10.8%) 
from lapsed blood donors. We observed a high seroprevalence rate in 
first-time donor group (p < 0.0001) when compared with regular and 
lapsed blood donors (data not shown). In the same period, there were 
301,470 first-time blood donations and, as previously mentioned, 296 
samples from first-time donors were HTLV-1/2 reactive. Therefore, the 
rate of HTLV-1/2 seroprevalence of first-time donors was 0.1% and this 
rate did not change over the years, with the exception of 2000 (0.2%) 
(Table 1). All the results shown below are related to the data obtained 
from first-time donors. 
Age and gender distribution: The mean age of subjects with HTVL-
1/2-reactive samples was 35.2 years throughout the 11 years of the study 
(Table 1). To investigate the prevalence in different age groups, we divided 
these subjects into four groups: i) 18-29, ii) 30-39, iii) 40-49 and iv) > 50 
years old (Table 1). Of the 296 first-time donors with HTLV-1/2-reactive 
samples, the majority (37.2%) were young blood donors (18-29 years 
old) as supported by statistical analysis (p = 0.0455, Chi-square test). 
During the analyzed period, the majority of HTLV-1/2-seropositive 
individuals were females (51%). Our data demonstrated that from 2000 
to 2003 there were a higher frequency of males among HTLV-1/2-reactive 
blood donors (58%), and after this period there was a significant increase 
of HTLV-1/2-reactive females (p = 0.0410) (data not shown). 
PCR confirmatory tests: Some HTLV-1/2-positive samples 
identified on serologic screening were confirmed by in-house nested 
PCR. Of the 296 samples reactive to the EIA test, we tested 63 samples 
by PCR that returned to the institution for a second blood collection. The 
results showed that 28 samples were HTLV-1 positive, 13 were HTLV-2 
positive, three were indeterminate, and 19 were negative (Fig. 1).
Coinfection: A total of 47 donors HTLV-1/2-positive were coinfected 
with more than one serological marker (Fig. 1). The coinfection rate 
was 15.9% (n = 47) among HTLV-1/2-reactive samples (n = 296) 
considering a reactive test for another serological marker (Table 2). 
Of the 47 HTLV1/2 positive samples, 39 were reactive for a second 
serological marker, among them 51.3%, 35.9%, 7.7%, 2.6%, and 2.6% 
Table 1
Distribution of blood donations during 11 years in the Regional Blood Center of Ribeirão Preto: characterization of first-time blood donors, seroprevalence rate of 
HTLV-1/2 and annual distribution of HTLV-1/2 seroprevalence rate according to the age
Year Donations (n) First-time donations
First-time do-
nors reactive 
for HTLV-1/2
HTLV-1/2 Se-
roprevalence 
(%)
Mean age of first-
time donors reac-
tive for HTLV-1/2
Age
18-29 30-39 40-49 >50
2000 80,846 30,459 54 0.2 34.5 21 11 19 3
2001 93,808 33,024 39 0.1 35.3 14 10 8 7
2002 103,125 33,363 24 0.1 38.1 6 6 8 4
2003 109,006 32,954 34 0.1 33.5 11 16 6 1
2004 103,049 29,585 23 0.1 34.4 10 6 6 1
2005 88,385 23,884 12 0.1 34.0 5 4 2 1
2006 88,133 23,182 25 0.1 36.3 10 6 7 2
2007 90,048 23,729 18 0.1 30.2 11 4 1 2
2008 93,989 24,428 20 0.1 34.9 8 5 4 3
2009 92,627 22,809 19 0.1 38.3 6 4 1 8
2010 95,473 24,053 28 0.1 37.3 8 8 7 5
Total 1,038,489 301,470 296 - 35.2 110 (37.2%) 80 (27%) 69 (23.3%) 37 (12.5%)
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being reactive for anti-HBc, anti-HCV, syphilis, anti-HIV-1/2 and Chagas 
disease, respectively (Fig. 2). 
Besides these cases, we identified six blood donors with triple 
serological markers: one with anti-HTLV-1/2, anti-HBc and syphilis; 
one with anti-HTLV-1/2, anti-HBc and HBsAg; one with anti-HTLV-1/2, 
anti-HCV and anti-HIV-1+2; three with anti-HTLV-1/2, anti-HCV and 
anti-HBc. We also identified two blood donors with reactivity for four 
serological markers (one donor with anti-HTLV-1/2, anti-HIV-1+2, anti-
HBc and anti-HCV; one with anti-HTLV-1/2, anti-HIV-1+2, anti-HBc 
and syphilis). 
The results showed that most coinfections predominated among 
males (59.6%). The two blood donors candidates who presented reactive 
serology for four markers were males (data not shown).
DISCUSSION
In this study, during 11 years of follow-up (January, 2000 to 
December, 2010), we observed a HTLV-1/2 seroprevalence of 0.1% in 
the Northwest region of São Paulo State. This seroprevalence rate is 
higher than cities such as Manaus (0.08%), located in Amazonas State, 
and Florianópolis (0.08%), located in Santa Catarina State19. In addition, 
this seroprevalence is lower than São Paulo (0.2%)17 and Recife city 
(0.33%)19 and even lower than Salvador city (1.35%)19, confirming that 
this retrovirus has a heterogeneous distribution in Brazil.
Our data demonstrated that most HTLV-infected individuals were 
Fig. 1. Flowchart of samples of blood donation which were HTLV-1/2-reactive. SM: 
serological markers, +: reactive or positive; -: negative; PCR: in-house polymerase chain 
reaction.
Table 2
Distribution of coinfection markers per year and frequencies rate in relation to gender
Year Male Female HBV HCV HIV SYP CD anti-HBc/HBsAg
anti-HBc/
HCV
anti-HBc/
SYP HCV/HIV
anti-HBc/
HIV/SYP
anti-HBc/
HIV/HCV
2000 8 2 4 3 - 1 - - - - - 1 1
2001 7 2 4 3 - 1 - - - 1 - - -
2002 - 1 - 1 - - - - - - - - -
2003 5 0 1 2 - - 1 - - - 1 - -
2004 2 1 - - 1 - - 1 1 - - - -
2005 1 1 2 - - - - - - - - - -
2006 2 1 2 - - 1 - - - - - - -
2007 1 1 1 1 - - - - - - - - -
2008 1 1 - 2 - - - - - - - - -
2009 0 4 3 - - - - - 1 - - - -
2010 1 5 3 2 - - - - 1 - - - -
Total 28 19 20 14 1 3 1 1 3 1 1 1 1
HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; SYP: syphilis; CD: Chagas disease.
Fig. 2 - Coinfection rate of HTLV-1/2-reactive samples with hepatitis B virus (HBV), hepatitis 
C virus (HCV), human immunodeficiency virus (HIV), syphilis and Chagas disease. 
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first-time blood donors (76.5%). We also observed that HTLV-1/2 
seroprevalence increased among females during the last seven years. This 
fact could be explained by the increase in the number of female blood 
donors and also by the high efficiency in male to female transmission22. 
Our data showed the higher frequency of seropositivity (37.2%) among 
young blood donors (18-29 years old). In fact, the most common blood 
donors’ age in The Regional Blood Center of Ribeirão Preto is 18-29 
years old and this could explain our finding. 
Our data also revealed that the older the individual (> 50 years old), 
the lower the HTLV prevalence (15.5%). Our findings disagree with those 
previously described by CATALAN-SOARES et al. (2001)12, who stated 
that HTLV prevalence increases with age. These findings clearly showed 
that the profile of HTLV-1-infected individuals is distinct among regions, 
reinforcing the importance of prevalence studies.
The Health Ministry only recommends EIA for HTLV-1/2 screening 
of blood donors. Although EIA is highly sensitive, it has a low positive 
predictive value, especially in low prevalence populations38. Because of 
this, it is necessary to perform confirmatory HTLV tests which, however, 
are not mandatory by Brazilian law. In this study, we also evaluated the 
use of a confirmatory test: in-house PCR. 
Of the 296 samples that were EIA reactive, 63 were tested by in-house 
PCR and we were able to determine the result of 60 samples (95%). 
Moreover, our in-house PCR was able to discriminate between HTLV-1 
and HTLV-2. Only three samples were considered to be indeterminate, 
demonstrating that the molecular test is a sensitive and accurate test. 
In recent years, molecular methods started to be used to confirm 
HTLV infection status. In parallel, serologic screening tests have 
undergone a significant evolution, preventing a large number of false-
positive results in EIA tests. These false-positive results are a problem 
for blood banks because they cause blood components to be discarded 
and donors to be rejected as unsuitable for future blood donations. 
We observed a seroprevalence rate of HTLV-1/2 coinfection higher 
than 10% in Ribeirão Preto and region. According to the CASOLI et 
al. (2007)10, HTLV-1/2 coinfection has emerged as a worldwide health 
problem in the last 20 years, with increasing numbers of HIV/HTLV-1-
infected individuals in South America and Africa and of HIV/HTLV-2-
infected individuals in the US and Europe10. 
The association of HTLV-1/2 with other infectious agents deserves 
special attention since the interaction between these pathogens may 
harm patients by stimulating the development of further therapeutic 
complications, progression of neurologic and immunological disorders 
and of liver dysfunction.
Our results demonstrated that there are HTLV-positive individuals 
who had dual serological markers, and most of them (51.3%) were 
coinfected with HBV. These two infections share the same routes of 
transmission and coinfected cases may be detected in populations that 
are highly exposed to common risk factors. The diagnosis of HTLV/
HBV in Brazilian blood banks and hospitals is important in view of the 
risk of blood-borne disease transmission24,36. 
The second most frequent marker among HTLV-positive individuals 
was anti-HCV (35.9%). Some studies have demonstrated that HTLV/
HCV-coinfected individuals diverge in laboratory parameters, involving 
both liver and immunological patterns. HTLV/HCV coinfection can 
involve a worse prognosis for HCV infection6,8,41.
Another important association is HTLV/HIV coinfection, which 
induces severe clinical manifestations and opportunistic pathogenic 
infections20. We observed that 2.6% of HTLV positive subjects are anti-
HTLV-1/2 and anti-HIV-1/2-reactive. In the state of Bahia, the prevalence 
of HTLV coinfection reached 20% among HIV-infected individuals and 
4.7% among women from Feira de Santana city7. Some research has 
shown that HTLV-1 coinfection accelerates the progression of AIDS7, and 
a recent review reported that overexpression of the HTLV-1/2 Tax proteins 
seem to play a crucial role in the clinical and immunologic manifestations 
of HIV/HTLV-1/2 coinfections3. However, other authors have suggested 
that it has no deleterious effects on HIV-1 disease38. Due to the impact 
of HTLV/HIV coinfection in disease progression, it would be important 
to investigate the coinfection prevalence in different regions and also 
to adapt public health policies and to provide appropriate programs for 
the treatment of patients. Interestingly, most cases of coinfection were 
observed in 2000 and 2001, an occurrence possibly explained by the fact 
that serological tests have become more efficient over the years. 
A shortcoming of this study was that the confirmatory PCR was 
not performed in all HTLV-1/2 EIA-reactive samples. This is due to 
the fact that this confirmation is not compulsory for the Brazilian blood 
bank. Moreover, once the primary test is positive, the majority of the 
donors did not return (233 HTLV-1/2 EIA positive blood donors) to the 
institution for a second diagnostic blood collection, although an attempt 
had been made for them to return. The other infectious diseases (HCV, 
HBV, HIV-1/2, syphilis and Chagas disease) were tested at our institution 
only serologically, because their consecutive confirmation is made in the 
respective reference centers.
Although HTLV infection is an emergent and endemic infectious 
disease in Brazil, there is no need to notify the National Sanitary 
Agency. Therefore, the real number of HTLV-infected individuals in 
the population is underestimated and epidemiological studies like ours 
are very informative.
RESUMO
Soroprevalência e taxa de coinfecção do HTLV-1/2 em doadores de 
sangue de primeira vez brasileiros: 11 anos de estudo
A soroprevalência e a distribuição geográfica do HTLV-1/2 entre 
os doadores de sangue são extremamente importantes para os serviços 
de transfusão. Neste trabalho, foi determinada a soroprevalência da 
infecção pelo HTLV-1/2 entre os doadores de sangue de primeira vez 
da cidade de Ribeirão Preto e região. No período de Janeiro de 2000 a 
Dezembro de 2010, 1.038.489 doações de sangue foram obtidas sendo 
301.470 doações de primeira vez. Todas as amostras foram avaliadas 
com testes sorológicos para HTLV-1/2 usando ensaio imunoenzimático 
(EIA). Adicionalmente, a frequência de coinfecção com o vírus da 
hepatite B (HBV), vírus da hepatite C (HCV), vírus da imunodeficiência 
humana (HIV), doença de Chagas (CD) e sífilis também foi determinada. 
Adicionalmente, foi utilizada uma reação de PCR in-house como teste 
confirmatório para HTLV-1/2. Um total de 296 (0,1%) doadores de 
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primeira vez foram sorologicamente reativos para HTLV-1/2. O PCR 
confirmatório de 63 amostras mostrou que 28 eram HTLV-1 positivas, 
13 HTLV-2 positivas, 19 negativas e três indeterminadas. Em relação 
às taxas de coinfecção com HTLV1/2, a maior prevalência foi com 
HBV (51,3%) e HCV (35,9%), mas a coinfecção com HIV, CD e sífilis 
também foram detectadas. O número real de indivíduos infectados pelo 
HTLV-1 e a taxa de coinfecção na população é subestimado e estudos 
epidemiológicos como esse são muito informativos. 
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